drugset / Trial / NCT01298700

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01298700

Phase 4 Completed 806 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.

Timeline

Start
2011-05-31
Primary completion
2016-12-06
Completion
2016-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.01 % Other
Subject Bimatoprost Other / unclassified 0.03 % Other